Monopar Therapeutics, Inc. (MNPR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$117.56-0.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Monopar is focused on developing cancer therapies and aims to extend funding through 2027. The company recently reported an earnings beat after several misses. It has announced a share buyback, signaling confidence in its future. Analysts have slightly improved earnings estimates over the past 30 days.
Monopar remains unprofitable with negative earnings expected through 2027. Revenue is minimal and uncertain, and the company has missed earnings multiple times recently. Funding beyond 2027 is not yet secured, posing a risk to operations.
The stock price is about 9% below our valuation level and in line with the Street median estimate. The market expects continued losses and limited growth, while we see potential if funding and development progress improve.
Breaks if: EPS loss worsens beyond -3.14 USD per share in FY27
Breaks if: funding not secured through 2027
Ensure current funds are sufficient to support operations through December 31, 2027.
Breaks if: revenue fails to exceed $15.8 million in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround situation, as MNPR is currently loss-making and has weak recent financial performance. The current thesis state is cautious, with a watchful eye on management's ability to execute on key priorities.
The market appears to have low expectations for MNPR, given the recent changes in confidence and the fragility tier being low. There is no indication of significant fragility in the current pricing, suggesting that the stock is not overly sensitive to negative news.
Fundamentals may remain weak in the near term, especially given the elevated risk and the mixed status of management's priorities. The probability of missing expectations is low, but the industry has seen peers struggle, which could impact MNPR.
The long-term thesis hinges on several factors, including the successful advancement of ALXN1840's regulatory approval, the demonstration of its clinical benefits, and the overall performance of the healthcare sector. Additionally, any guidance cuts or worsening economic indicators could negatively affect sentiment.
In the next 1 to 3 years, MNPR's outlook will depend heavily on management's execution and sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that would weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.